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' ' ' ' or'higher'(lower'versions'may'work'but'are'untested),'
' ' ' ' Bowtie'or'BWA'(versions'0.12.7'or'0.5.9Dr16,'respectively),'or'
' ' ' ' another'SAMDcompatible'alignment'algorithm'
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Formula'3.3)' R = L - (MA * 2)





























































































































































































Align RNA-seq reads to
the Indexed Genome
2. DISCOVER
Discover Novel Splice Junctions with High
Stringency (≥1 read spanning by ≥ 12nt)




Align RNA-seq reads to
the SJ-Indexed Genome
4. QUANTIFY
Quantify Splice Junctions with Lower
Stringency (# reads spanning by ≥ 3nt)
Index the Genome with















































Improvement in Accuracy, relative to Read Depth













Cumulative Percentage of Splice Junctions





































De Novo 1−pass A549(101nt)
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Spanning by <= 12nt
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TCGA25025933_T! Lung!Adenocarcinoma!Tissue! 48! 48nt! 99%! 1.68x! 1.75x!TCGA25025933_N! Lung!Normal!Tissue! 52! 98%! 1.71x!









NCI2H358! 109! 97%! 1.19x!
NCI2H460! 105! 97%! 1.19x!
NCI2H1437! 76! 97%! 1.19x!
AT_flowerbuds! Arabidopsis!Flower!Buds! 192! 97%! 1.12x!





































































































































































































































































































































































































































1:2 + 3:6 1:4 + 5:6
1:2 + 3:6 1:2 + 3:2+ 3:4































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































pearson r^2 = −0.912

















67,690 kb 67,700 kb 67,710 kb
28 kb
chrX


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































ALK Fusion (Any Partner & Orientation)
ATI Expressed (FPKM: ATI >= 1 & ATI >= 1/4 Downstream)
ATI Not Expressed
Gene FPKM :  31.075
5' FPKM :  5.383
ATI FPKM :  40.017
3' FPKM :  80.023
































































































































































































































































































































Count Unspliced Read Depth over Spliced Positions
































































































































































































0 VF = 91%
VF = 74%
VF = 88%





















Ref. Var. VF -log10(p)
2172
Outlier Calls
Differential Call, -log10(p) :






























































































































































UTR Read Depth Outliers
PolyA Libraries





















































































































































































Gene Annotated Spliced ATSS AR Tumor CRPC PrEC TCGA.N UM.N TCGA.T UM.T SU2C
ACSL5 no no yes yes 0% 2% 4% 25% 18% 15%
ACSM1 yes yes yes yes - 13% 17% 82% 78% 68%
ARHGEF26* no no yes yes 0% 28% 9% 74% 46% 33%
CPNE4 no yes yes yes 0% 3% 2% 16% 14% 16%
MAD2L2 yes yes yes no 3% 5% 7% 16% 18% 20%
PDLIM5 no no yes yes 1% 10% 20% 62% 73% 57%
PEX10 no no yes yes 24% 22% 8% 49% 25% 34%
PRKACB yes yes yes yes 6% 22% 12% 47% 37% 39%
TPM1 yes yes yes no 19% 5% 6% 22% 29% 53%
TRPM4 no no yes no 4% 2% 2% 34% 21% 21%
v : two-fold down,  ^ : two-fold up, ^^ : five-fold up, blank : unchanged ( )
*called in 3/4 met sites in SU2C, detected in 4/4










































































































































































































Genome RNA-Seq Chipseq Exome
Oculus performance statistics #1 #2 #3 #1 #2 #3 #4 #5 #1 #2 #1 #2 #3
Run MDA-MB-231 (IDEA) T-47D (IDEA) ERR000589 Bodymap MDA-MB-231 T-47D BT-20 BT-474 Broad - H3k4-me3 Uw - TFBS SRR098490 SRR098492 SRR171306
Sequence read archive accession id SRR097850 SRR097852 ERR000589 ERS025093 SRR097790 SRR097792 SRR097786 SRR097787 SRR227346
SRR299316 + 
SRR299313 SRR098490 SRR098492 SRR171306
total # of reads (millions) 25 27 24 385 79 83 84 81 37 66 260 272 154
read length 50 50 51 100 50 50 50 50 36 36 76 76 50
SE % unique 93.6% 93.4% 95.5% 69.3% 31.7% 31.6% 32.4% 49.3% 95.9% 35.0% 81.4% 82.1% 87.0%
%error 0.03% 0.03% 0.03% 0.002% 0.11% 0.12% 0.11% 0.13% 0.002% 0.02% 0.01% 0.008% 0.006%
Bowtie CPU runtime (hours) 0.48 0.58 0.63 29.81 1.68 1.99 1.76 2.35 1.60 1.37 13.19 13.61 8.35
(Oculus wrapping Bowtie) CPU runtime (hours) 0.49 0.54 0.62 24.83 0.76 0.75 0.78 1.53 1.77 0.37 12.56 13.90 8.47
%runtime 102.7% 92.8% 97.7% 83.3% 45.1% 38.0% 44.0% 64.9% 110.4% 27.0% 95.3% 102.2% 101.5%
BWA CPU runtime (hours) 2.35 2.97 2.61 146.65 7.03 7.43 8.03 9.63 2.09 2.81 39.66 41.81 26.49
(Oculus wrapping BWA) CPU runtime (hours) 2.28 2.75 2.56 116.39 3.03 2.88 3.32 5.73 2.07 1.23 35.22 38.29 25.06
%runtime 97.0% 92.5% 98.0% 79.4% 43.1% 38.8% 41.3% 59.5% 99.0% 43.9% 88.8% 91.6% 94.6%
PE % unique 98.5% 98.4% 99.7% 77.0% 74.7% 77.0% 87.0% 96.0% 95.3%
%error 0.0004% 0.001% 0.001% 0.08% 0.08% 0.08% 0.04% 0.004% 0.004%
Bowtie CPU runtime (hours) 4.00 4.36 1.74 5.25 5.11 5.16 6.28 20.51 22.31
(Oculus wrapping Bowtie) CPU runtime (hours) 3.76 4.11 1.72 3.94 4.37 4.31 5.82 20.33 21.93
%runtime 94.2% 94.2% 98.9% 75.1% 85.4% 83.5% 92.7% 99.2% 98.3%
BWA CPU runtime (hours) 2.81 3.28 3.09 9.42 9.15 9.25 11.38 42.02 44.27
(Oculus wrapping BWA) CPU runtime (hours) 2.69 3.11 3.02 7.61 7.09 7.69 10.28 42.17 44.51









sample name sample description read pairs read length quality scores Instrument organism publication repository tcga_legacy_id aliquot_id analysis_id
TCGA-50-5933_T Lung Adenocarcinoma 48,114,428 TCGA-50-5933-01A-11R-1755-07 51eae0de-8f16-4093-b42e-5c34c4768459 689f917d-acf9-4381-8e3b-340802913bb2
TCGA-50-5933_N Lung Normal 52,241,489 TCGA-50-5933-11A-01R-1755-07 af24ffd8-4d43-4f7a-ae49-590814d00f39 38fc3e2d-2b7f-43fd-a73f-b97616281c3b
A549 Lung Adenocarcinoma cell line 92,208,573 CCLE-A549-RNA-08 ee57b244-8714-4e31-91bf-b60a4e931e99 994e9332-44ec-4f65-a926-b0b0360df5f5
NCI-H358 Bronchioalveolar carcinoma cell line 109,186,348 CCLE-NCI-H358-RNA-08 7e674991-a125-4757-896a-04726ecbaef7 38883661-8ffa-4c54-8691-5998bf22f2e4
NCI-H460 Large cell lung carcinoma cell line 105,408,628 CCLE-NCI-H460-RNA-08 5e90e8d2-08bf-4f1f-a047-b4f786b6aa4f 73045153-e0f8-43a6-ae22-f1ecd7ce775a
NCI-H1437 Lung Adenocarcinoma cell line 76,199,681 CCLE-NCI-H1437-RNA-08 5b4a5e81-d9fb-42ca-a329-7d011e443f3e 39c19460-909e-47df-892d-86638ddd5969
SRA_id library_names
LC_S22_T Lung Adenocarcinoma 52,237,502 ERR164604 LC_S22_Txn1
LC_S22_N Adjacent Lung Normal 34,871,202 ERR164519 LC_S22_nor_Txn1
AT_flowerbuds Arabidopsis Flower buds 192,420,769 SRR1061357 Flower Buds replicate 1


























HiSeq 2500: TruSeq Stranded




























runMode alignReads #alignment mode, contrasted with indexing
runThreadN 8 #processes used
limitGenomeGenerateRAM 31000000000 #memory limit




sjdbOverhang 125 #maximum spliceable read length, used in indexing
outFilterType BySJout #force reported reads to meet standard reporting criteria for splice junctions
alignIntronMin 20 #minimum intron size STAR can align to / discover
alignIntronMax 1000000 #maximum intron size STAR can align to / discover
alignMatesGapMax 1000000 #maximum intron size STAR can align to / discover
alignSJoverhangMin 8 #minimum number of nucleotides a read is allowed to span a NOVEL splice junction by
alignSJDBoverhangMin 3 #minimum number of nucleotides a read is allowed to span a KNOWN splice junction by (ENCODE used 1)
scoreGenomicLengthLog2scale 0 #apply no penalty to longer introns compared with shorter introns (> 1000000 still disallowed, see above)
#reduce SAM file output size, does not affect results
#basic logistic parameters, none of which affect results
#ENCODE parameters
#default - differing from ENCODE































































































Splice Junctions missed by De Novo 2pass
















































































cohort sample RIN Gleason Biopsy.Site Subtype TC 3' Nascent Aln% AR Stroma NE
TCGA.T 2A@A8VL 8.7 3+3 Prostate 1.ERG 0.51 0.93 0.00 0.91 2.18 @0.21 0.04
TCGA.T 2A@A8VT 9 4+3 Prostate 1.ERG 0.73 0.45 0.00 0.91 @0.18 @3.35 0.79
TCGA.T 2A@A8VV 8.5 3+3 Prostate 1.ERG 0.84 0.87 0.00 0.87 1.94 0.63 1.21
TCGA.T CH@5739 8.3 4+3 Prostate 1.ERG 0.69 0.74 0.00 0.91 1.64 0.66 0.58
TCGA.T CH@5740 7.2 4+4 Prostate 1.ERG 0.69 0.85 0.00 0.80 1.41 @2.56 @0.66
TCGA.T CH@5741 7.6 5+4 Prostate 1.ERG 0.82 1.02 0.00 0.90 2.41 @5.74 1.97
TCGA.T CH@5743 7.2 4+3 Prostate 1.ERG NA 0.96 0.00 0.92 @2.6 4.87 @3.43
TCGA.T CH@5744 7.4 4+4 Prostate 1.ERG 0.60 0.74 0.00 0.91 1.04 @3.53 1.41
TCGA.T CH@5746 7.5 3+3 Prostate 1.ERG 0.36 0.84 0.00 0.89 1.76 @0.22 @0.11
TCGA.T CH@5752 9.2 5+4 Prostate 1.ERG 0.79 0.78 0.00 0.90 0.28 @2.25 0.45
TCGA.T CH@5754 8.4 4+4 Prostate 1.ERG 0.65 0.74 0.00 0.90 @0.31 @1.57 1.11
TCGA.T CH@5764 8.8 3+4 Prostate 1.ERG 0.56 0.77 0.00 0.87 0.88 @0.08 @0.15
TCGA.T CH@5765 8.3 3+4 Prostate 1.ERG 0.76 0.84 0.00 0.89 1.47 @2.09 1.45
TCGA.T CH@5766 9 4+3 Prostate 1.ERG 0.61 0.81 0.01 0.89 1.06 @1.73 @0.62
TCGA.T CH@5768 8.5 3+3 Prostate 1.ERG 0.70 0.93 0.00 0.89 1.83 @2.76 1.1
TCGA.T CH@5769 8.2 4+5 Prostate 1.ERG 0.63 0.84 0.00 0.88 @1.13 0.33 0.94
TCGA.T CH@5789 8.5 4+3 Prostate 1.ERG NA 0.77 0.00 0.90 1.97 3.01 @2.27
TCGA.T CH@5790 8.9 3+4 Prostate 1.ERG 0.81 0.72 0.00 0.88 2.11 @3.26 1.48
TCGA.T CH@5791 8.1 4+3 Prostate 1.ERG 0.67 0.76 0.00 0.88 0.47 @2.76 1.19
TCGA.T CH@5794 7.9 4+3 Prostate 1.ERG 0.58 0.79 0.00 0.92 @0.27 @1.88 0.26
TCGA.T EJ@5495 8.8 4+5 Prostate 1.ERG 0.41 0.70 0.00 0.90 @0.64 4.85 @3.49
TCGA.T EJ@5496 8.4 3+3 Prostate 1.ERG 0.49 0.91 0.00 0.87 3.35 @1.34 0.4
TCGA.T EJ@5497 9 3+4 Prostate 1.ERG 0.46 0.77 0.00 0.89 3.67 1.49 @1.78
TCGA.T EJ@5498 9 3+4 Prostate 1.ERG 0.24 0.90 0.00 0.89 1.08 6.31 @4.51
TCGA.T EJ@5499 8.3 3+4 Prostate 1.ERG 0.48 1.03 0.00 0.88 @0.6 0.3 @0.6
TCGA.T EJ@5502 8.1 3+4 Prostate 1.ERG NA 0.69 0.00 0.92 1.42 2.61 @2.29
TCGA.T EJ@5503 7.9 4+5 Prostate 1.ERG NA 0.75 0.00 0.93 2.31 4.53 @3.08
TCGA.T EJ@5506 9.1 4+3 Prostate 1.ERG NA 0.80 0.00 0.90 1.5 2.68 @2.19
TCGA.T EJ@5507 9.4 4+5 Prostate 1.ERG 0.68 0.85 0.00 0.91 @0.46 @1.72 0.2
TCGA.T EJ@5508 8.3 3+4 Prostate 1.ERG 0.36 0.77 0.00 0.89 2.03 1.76 @1.45
TCGA.T EJ@5512 7.8 3+3 Prostate 1.ERG 0.39 1.13 0.00 0.89 1.74 3.53 @1.85
TCGA.T EJ@5516 9.1 4+3 Prostate 1.ERG 0.39 0.81 0.00 0.91 1.98 1.74 @1.64
TCGA.T EJ@5521 8.2 4+4 Prostate 1.ERG 0.51 0.89 0.00 0.93 @0.51 @0.52 @0.18
TCGA.T EJ@5522 9.6 3+4 Prostate 1.ERG 0.51 0.78 0.00 0.92 2.43 1.25 @1.98
TCGA.T EJ@5524 9.6 4+3 Prostate 1.ERG 0.54 0.82 0.00 0.92 1.71 2.68 @0.96
TCGA.T EJ@5525 9 4+5 Prostate 1.ERG 0.87 0.91 0.00 0.90 0.08 @1.07 1.57
TCGA.T EJ@5526 9 4+5 Prostate 1.ERG 0.51 0.81 0.00 0.91 2.12 2.67 @1.15
TCGA.T EJ@5527 9.5 4+3 Prostate 1.ERG 0.51 0.83 0.00 0.91 1.54 2.12 @2.12
TCGA.T EJ@5530 9.7 3+4 Prostate 1.ERG 0.53 0.54 0.00 0.92 2.58 @0.56 @1.03
TCGA.T EJ@5542 9.8 3+4 Prostate 1.ERG 0.58 0.92 0.00 0.92 2.7 1.32 @1.74
TCGA.T EJ@7314 8.4 4+3 Prostate 1.ERG 0.61 0.85 0.00 0.90 1.96 @2.06 0.37
TCGA.T EJ@7315 8.2 4+3 Prostate 1.ERG 0.65 0.89 0.00 0.90 @0.17 1.15 @0.78
TCGA.T EJ@7321 8.7 3+3 Prostate 1.ERG 0.72 0.82 0.00 0.90 0.93 @2.63 1.49
TCGA.T EJ@7327 9.5 4+3 Prostate 1.ERG 0.48 0.66 0.00 0.90 0.64 2.7 @2.02
TCGA.T EJ@7328 7.7 4+3 Prostate 1.ERG 0.44 0.79 0.00 0.89 @1.71 3.2 @1.04
TCGA.T EJ@7783 9.3 4+4 Prostate 1.ERG 0.41 0.72 0.00 0.90 0.75 3.08 @1.98






cohort sample RIN Gleason Biopsy.Site Subtype TC 3' Nascent Aln% AR Stroma NE
TCGA.T EJ@7785 9.4 3+3 Prostate 1.ERG 0.43 0.63 0.00 0.92 1.94 5.39 @1.8
TCGA.T EJ@7793 7.7 3+4 Prostate 1.ERG 0.33 0.82 0.00 0.92 4.05 2.42 @1
TCGA.T EJ@7797 8 3+4 Prostate 1.ERG 0.38 0.77 0.00 0.92 2.35 0.78 @1.22
TCGA.T EJ@8469 9.3 4+5 Prostate 1.ERG 0.79 0.68 0.00 0.92 2.01 @3.1 @0.31
TCGA.T EJ@8472 8.9 4+4 Prostate 1.ERG 0.75 1.08 0.00 0.91 0.59 0.57 1.18
TCGA.T EJ@A46D 7.2 3+3 Prostate 1.ERG 0.20 0.79 0.00 0.77 1.14 2.11 @1.73
TCGA.T EJ@A65F 8.1 4+3 Prostate 1.ERG 0.67 0.80 0.00 0.91 1.32 @1.45 @0.57
TCGA.T EJ@A7NF 8.6 3+4 Prostate 1.ERG 0.76 0.90 0.00 0.89 1.73 @3.66 2.1
TCGA.T EJ@A7NG 8 3+4 Prostate 1.ERG NA 0.69 0.00 0.89 @0.6 5.96 @3.57
TCGA.T EJ@A7NK 7.6 3+3 Prostate 1.ERG NA 0.87 0.00 0.79 0.26 4.1 @2.91
TCGA.T FC@7708 9.2 3+3 Prostate 1.ERG 0.43 0.76 0.00 0.91 0.91 3.56 @2.36
TCGA.T G9@6329 8 3+4 Prostate 1.ERG 0.29 1.11 0.00 0.89 @1.73 3.71 @2.68
TCGA.T G9@6336 7.7 3+3 Prostate 1.ERG 0.26 1.07 0.00 0.91 1.06 0.43 @0.42
TCGA.T G9@6342 8 4+3 Prostate 1.ERG 0.53 1.00 0.00 0.89 0.42 0.59 @0.78
TCGA.T G9@6351 8.5 3+3 Prostate 1.ERG 0.34 1.00 0.00 0.90 3.34 1.14 @0.61
TCGA.T G9@6353 7.9 3+3 Prostate 1.ERG NA 0.99 0.00 0.90 1.39 5.08 @2.55
TCGA.T G9@6356 8.7 3+4 Prostate 1.ERG 0.28 0.98 0.00 0.89 @1.14 2.71 @3.15
TCGA.T G9@6361 7.9 3+4 Prostate 1.ERG 0.71 1.03 0.00 0.91 0.37 3.65 @0.13
TCGA.T G9@6363 8.4 4+3 Prostate 1.ERG 0.51 1.07 0.00 0.89 @0.19 @0.43 0.5
TCGA.T G9@6364 8.8 3+4 Prostate 1.ERG 0.61 1.24 0.00 0.53 @1.02 4.44 @2.95
TCGA.T G9@6365 7.6 3+4 Prostate 1.ERG 0.54 1.08 0.00 0.90 @1.46 4.35 @2.6
TCGA.T G9@6377 8.2 3+4 Prostate 1.ERG 0.66 0.98 0.00 0.90 1.58 @2.45 0.88
TCGA.T G9@6384 9 3+4 Prostate 1.ERG 0.46 0.70 0.00 0.91 2.09 2.16 @1.06
TCGA.T G9@6385 7.4 3+4 Prostate 1.ERG NA 1.04 0.00 0.91 1.49 3.09 @2.32
TCGA.T G9@7522 8.7 3+4 Prostate 1.ERG 0.41 0.82 0.00 0.93 1.72 2.32 @1.31
TCGA.T HC@7077 8 3+4 Prostate 1.ERG 0.78 0.71 0.00 0.90 2.58 @5.76 3.68
TCGA.T HC@7081 9.2 4+3 Prostate 1.ERG 0.57 0.57 0.00 0.92 @0.32 2.37 @1.76
TCGA.T HC@7209 9.1 3+4 Prostate 1.ERG 0.57 0.59 0.00 0.91 1.63 @1.66 @0.43
TCGA.T HC@7211 9.5 4+5 Prostate 1.ERG 0.69 0.67 0.00 0.91 2.33 @2.29 0.61
TCGA.T HC@7212 9.6 4+4 Prostate 1.ERG 0.81 0.62 0.00 0.91 2.5 @3.25 1.13
TCGA.T HC@7213 9.4 4+5 Prostate 1.ERG 0.78 0.74 0.00 0.92 0.87 @1.46 1.52
TCGA.T HC@7230 9.1 3+3 Prostate 1.ERG 0.85 0.78 0.00 0.92 2.99 @3.45 2.04
TCGA.T HC@7231 8.4 3+4 Prostate 1.ERG 0.75 0.75 0.00 0.91 0.56 @2.49 0.26
TCGA.T HC@7232 9.1 3+4 Prostate 1.ERG 0.60 0.79 0.00 0.92 0.71 1.82 @1.24
TCGA.T HC@7744 8.8 4+5 Prostate 1.ERG 0.82 0.75 0.00 0.91 1.49 @3.38 1.54
TCGA.T HC@7747 7.9 3+4 Prostate 1.ERG 0.38 0.83 0.00 0.90 1.42 @0.14 @2.18
TCGA.T HC@7748 9.6 3+4 Prostate 1.ERG 0.50 0.60 0.00 0.92 2.55 2.06 @1.39
TCGA.T HC@7818 8 3+3 Prostate 1.ERG NA 0.77 0.00 0.92 1.06 0.65 @1.03
TCGA.T HC@7820 7.8 3+3 Prostate 1.ERG 0.48 0.75 0.00 0.91 3.51 @1.02 @0.65
TCGA.T HC@7821 7.5 4+5 Prostate 1.ERG 0.85 0.71 0.00 0.91 1.63 @1.81 @0.72
TCGA.T HC@8213 8.3 3+3 Prostate 1.ERG 0.86 1.16 0.00 0.89 1.61 @5.38 0.3
TCGA.T HC@8257 7.7 3+4 Prostate 1.ERG 0.74 0.91 0.00 0.91 0.89 @3.01 @0.46
TCGA.T HC@8260 8.1 3+3 Prostate 1.ERG NA 0.93 0.01 0.87 2.47 0.89 @1.23
TCGA.T HC@8262 8.7 3+4 Prostate 1.ERG 0.57 0.97 0.00 0.90 0.92 @1.76 @0.61
TCGA.T HC@A48F 9.2 4+3 Prostate 1.ERG 0.91 0.97 0.00 0.92 0.02 @4.31 1.1
TCGA.T HC@A632 8.4 4+5 Prostate 1.ERG 0.71 0.88 0.00 0.89 0.41 @0.61 0.64





cohort sample RIN Gleason Biopsy.Site Subtype TC 3' Nascent Aln% AR Stroma NE
TCGA.T HC@A8D0 8.6 4+4 Prostate 1.ERG 0.44 0.79 0.00 0.90 @2.68 2.43 @1.15
TCGA.T HC@A8D1 9.1 3+4 Prostate 1.ERG 0.42 0.69 0.00 0.90 0.6 1.59 @1.08
TCGA.T HI@7171 9 4+4 Prostate 1.ERG 0.88 0.97 0.00 0.90 0.19 @2.78 1.94
TCGA.T J4@8198 9.2 3+4 Prostate 1.ERG 0.68 0.80 0.00 0.90 0.91 1.8 @0.57
TCGA.T J4@A67T 7.9 3+4 Prostate 1.ERG 0.51 0.99 0.00 0.91 1.43 0.3 @0.42
TCGA.T J4@A6G1 8.4 4+3 Prostate 1.ERG 0.45 1.00 0.00 0.89 @1.46 2.95 @1
TCGA.T J4@A6M7 8.9 3+3 Prostate 1.ERG 0.81 0.79 0.00 0.91 2.59 @0.64 0.06
TCGA.T J4@A83I 9.5 4+3 Prostate 1.ERG 0.82 0.66 0.00 0.90 1.03 @2.66 0.89
TCGA.T J4@A83K 9.3 3+3 Prostate 1.ERG 0.60 0.72 0.00 0.90 0.94 3.4 @0.64
TCGA.T J4@A83N 9.2 3+3 Prostate 1.ERG 0.62 0.94 0.00 0.86 2.36 @3.74 1.6
TCGA.T J9@A52B 8.1 4+5 Prostate 1.ERG 0.64 1.07 0.00 0.91 @1.44 @0.55 @3.84
TCGA.T J9@A8CK 7.3 4+3 Prostate 1.ERG 0.56 0.85 0.00 0.87 @0.75 2.81 @0.94
TCGA.T J9@A8CM 8.4 3+4 Prostate 1.ERG 0.64 0.64 0.00 0.81 @2.4 3.05 @0.81
TCGA.T KC@A4BN 8.6 3+3 Prostate 1.ERG 0.32 0.94 0.00 0.91 2.89 @1.6 0.78
TCGA.T KC@A4BR 7.1 3+4 Prostate 1.ERG NA 0.56 0.00 0.88 @1.19 6.63 @2.14
TCGA.T KC@A4BV 8.9 4+3 Prostate 1.ERG 0.67 0.81 0.00 0.91 0.18 0.54 @0.9
TCGA.T KC@A7F6 8.1 3+4 Prostate 1.ERG 0.66 0.86 0.00 0.88 @0.12 @0.08 0.36
TCGA.T KK@A59Y 9.5 4+5 Prostate 1.ERG 0.77 1.08 0.00 0.91 0.44 @3.99 1.4
TCGA.T KK@A6DY 7.8 3+4 Prostate 1.ERG 0.47 0.87 0.01 0.91 @0.52 @0.54 1.21
TCGA.T KK@A6E1 8.8 4+5 Prostate 1.ERG 0.74 0.82 0.00 0.91 1.31 @5.47 2.2
TCGA.T KK@A6E2 8.5 3+4 Prostate 1.ERG 0.86 0.71 0.00 0.90 1.63 @4.7 2.4
TCGA.T KK@A6E6 8.3 4+3 Prostate 1.ERG 0.46 0.97 0.00 0.91 @0.63 0.3 @0.15
TCGA.T KK@A7AU 8.9 4+3 Prostate 1.ERG 0.86 0.82 0.00 0.91 1.15 @8.37 3.45
TCGA.T KK@A7B1 9.1 4+3 Prostate 1.ERG 0.57 0.79 0.00 0.92 0.05 1.35 @0.53
TCGA.T KK@A7B4 9.1 4+5 Prostate 1.ERG 0.74 0.77 0.00 0.91 @0.19 @3.67 1.87
TCGA.T KK@A8I4 7.6 4+3 Prostate 1.ERG 0.43 0.66 0.00 0.91 @1.7 2.94 @0.66
TCGA.T KK@A8I5 8 3+3 Prostate 1.ERG 0.85 0.82 0.00 0.88 0.77 0.37 0.22
TCGA.T KK@A8I6 8.1 4+3 Prostate 1.ERG 0.68 0.74 0.00 0.88 2.26 @2.6 0.74
TCGA.T KK@A8I8 8.4 3+4 Prostate 1.ERG 0.74 0.83 0.00 0.88 @0.62 @3.06 1.4
TCGA.T KK@A8IA 8 4+4 Prostate 1.ERG 0.87 0.82 0.00 0.91 0.4 @4.24 3.08
TCGA.T KK@A8IC 8.2 4+3 Prostate 1.ERG 0.40 0.62 0.00 0.92 0.93 2.12 @0.73
TCGA.T KK@A8IH 9.3 4+3 Prostate 1.ERG 0.82 0.80 0.00 0.86 @1.74 @2.47 0.8
TCGA.T KK@A8II 10 3+4 Prostate 1.ERG 0.93 0.74 0.00 0.92 1.35 @6.33 2.41
TCGA.T M7@A720 8.8 3+3 Prostate 1.ERG NA 0.73 0.00 0.92 0.86 4.96 @2.4
TCGA.T QU@A6IP 8.1 3+3 Prostate 1.ERG 0.58 1.07 0.00 0.90 1.43 0 @0.38
TCGA.T V1@A8WS 9.1 4+3 Prostate 1.ERG 0.78 0.70 0.00 0.90 @0.59 @2.83 2.16
TCGA.T V1@A8WW 7.4 4+5 Prostate 1.ERG 0.84 0.79 0.00 0.90 @1.22 @1.1 0.55
TCGA.T VN@A88K 8.3 4+4 Prostate 1.ERG 0.82 0.73 0.00 0.85 0.58 @1.79 0.52
TCGA.T VN@A88L 7.5 3+4 Prostate 1.ERG 0.64 0.85 0.00 0.85 @0.28 1.99 @1.18
TCGA.T VN@A88Q 8.4 4+3 Prostate 1.ERG 0.68 0.74 0.00 0.87 0.82 @3.81 0.65
TCGA.T VP@A872 7.6 3+4 Prostate 1.ERG 0.62 0.98 0.00 0.86 @3.53 1.24 0.2
TCGA.T VP@A875 9.5 4+3 Prostate 1.ERG 0.98 0.64 0.00 0.90 3.14 @6.5 2.83
TCGA.T VP@A876 9.1 4+3 Prostate 1.ERG 0.89 0.90 0.00 0.90 0.42 @3.62 0.85
TCGA.T VP@A879 8.8 4+3 Prostate 1.ERG 0.49 0.51 0.00 0.89 0.45 4.91 @3.02
TCGA.T VP@A87C 8.9 4+4 Prostate 1.ERG 0.43 0.70 0.00 0.86 @1.43 3.16 @2.29
TCGA.T VP@A87D 9 4+4 Prostate 1.ERG 0.77 0.72 0.00 0.91 1.87 @3.45 0.89






cohort sample RIN Gleason Biopsy.Site Subtype TC 3' Nascent Aln% AR Stroma NE
TCGA.T XJAA9DI 7.8 5+5 Prostate 1.ERG NA 0.87 0.01 0.91 A2.46 4.06 A2.09
TCGA.T XJAA9DK 8.4 4+3 Prostate 1.ERG NA 0.71 0.00 0.89 A0.43 3.66 A1.99
TCGA.T XQAA8TB 7.9 3+4 Prostate 1.ERG 0.86 0.57 0.00 0.91 A0.59 0.76 0.25
TCGA.T YLAA8HJ 7.8 4+3 Prostate 1.ERG 0.36 0.56 0.00 0.88 A0.99 5.4 A2.48
TCGA.T YLAA8HK 7.8 4+4 Prostate 1.ERG 0.42 0.61 0.01 0.92 A0.66 3.32 A1.19
TCGA.T YLAA8HL 9.1 4+4 Prostate 1.ERG 0.85 0.64 0.00 0.89 0.38 A3.64 1.45
TCGA.T YLAA8SA 9.2 4+3 Prostate 1.ERG 0.82 0.67 0.00 0.90 A0.67 A5.36 2.02
TCGA.T YLAA8SF 8.4 4+3 Prostate 1.ERG 0.70 0.73 0.00 0.89 A2.23 A0.14 0.65
TCGA.T YLAA8SL 9.4 4+4 Prostate 1.ERG 0.77 0.69 0.00 0.89 A0.5 A5.38 2.56
TCGA.T YLAA8SP 9.2 4+5 Prostate 1.ERG 0.88 0.66 0.00 0.90 1.04 A4.61 1.26
TCGA.T ZGAA8QZ 8 3+4 Prostate 1.ERG 0.45 0.78 0.00 0.88 A0.68 2.88 A1.94
TCGA.T 2AAA8W1 8.6 4+4 Prostate 2.ETV1 0.95 0.68 0.00 0.91 4.62 A9.41 3.93
TCGA.T 2AAA8W3 8.8 5+4 Prostate 2.ETV1 0.46 0.57 0.00 0.87 1.49 A0.68 1.84
TCGA.T CHA5748 8.2 3+4 Prostate 2.ETV1 0.31 0.92 0.00 0.88 4.58 A2.32 1.4
TCGA.T CHA5750 8.3 3+4 Prostate 2.ETV1 0.75 0.93 0.00 0.89 2.25 A3.06 2.33
TCGA.T CHA5753 8.8 4+5 Prostate 2.ETV1 0.83 0.82 0.01 0.87 2.28 A4.54 1
TCGA.T EJA5501 8.2 3+4 Prostate 2.ETV1 0.40 0.75 0.00 0.92 0.05 0.47 A1.31
TCGA.T EJA5504 8.9 3+4 Prostate 2.ETV1 0.53 0.95 0.00 0.90 1.8 1.23 A0.79
TCGA.T EJA5510 8 4+3 Prostate 2.ETV1 0.40 0.82 0.00 0.92 1.29 1.25 A1.88
TCGA.T EJA5519 9.2 4+4 Prostate 2.ETV1 0.67 0.70 0.00 0.92 2.59 A1.59 1.01
TCGA.T EJA7318 8.3 3+3 Prostate 2.ETV1 0.63 1.00 0.00 0.91 2.62 A0.45 1.08
TCGA.T EJA7788 9.2 4+5 Prostate 2.ETV1 0.71 0.73 0.00 0.91 1.27 0.56 A1.01
TCGA.T EJA8474 8.5 3+4 Prostate 2.ETV1 0.45 0.97 0.00 0.90 1.15 1.52 0.84
TCGA.T EJAA7NH 7.8 3+4 Prostate 2.ETV1 0.41 0.66 0.01 0.90 2.01 1.3 A0.4
TCGA.T EJAA8FU 7.8 4+4 Prostate 2.ETV1 NA 0.68 0.00 0.89 0.37 6.43 A3.43
TCGA.T G9A6348 8 4+3 Prostate 2.ETV1 0.39 1.07 0.00 0.91 A0.24 1.37 A1.25
TCGA.T G9A6494 9.1 4+3 Prostate 2.ETV1 0.60 0.81 0.00 0.91 4.57 A0.15 0.37
TCGA.T HCAA631 8.4 3+4 Prostate 2.ETV1 0.92 0.89 0.00 0.89 0.56 A3.39 2.66
TCGA.T HCAA8CY 9 4+5 Prostate 2.ETV1 0.82 0.68 0.00 0.85 3.2 A5.65 2.47
TCGA.T J4AA83M 8.6 3+4 Prostate 2.ETV1 0.61 0.70 0.00 0.90 1.31 A2.28 0.72
TCGA.T KKAA7AP 8.9 3+4 Prostate 2.ETV1 0.90 0.54 0.00 0.90 0.17 A6.42 2.46
TCGA.T KKAA7B3 8.3 4+3 Prostate 2.ETV1 0.59 0.81 0.01 0.90 A0.94 A0.78 A0.49
TCGA.T M7AA71Y 7.3 3+3 Prostate 2.ETV1 0.17 0.90 0.00 0.91 A0.37 3.14 A2.16
TCGA.T SUAA7E7 8.7 3+4 Prostate 2.ETV1 0.40 0.71 0.00 0.90 0.08 A0.13 A0.75
TCGA.T V1AA8MJ 7.3 3+3 Prostate 2.ETV1 0.27 0.72 0.00 0.91 0.26 1.45 A1.11
TCGA.T VPAA87J 8.9 4+3 Prostate 2.ETV1 0.84 0.75 0.00 0.90 2.3 A3.92 1.4
TCGA.T YLAA8SC 9.2 4+4 Prostate 2.ETV1 0.66 0.69 0.00 0.92 0.8 A2.61 1.77
TCGA.T YLAA8SJ 8.3 4+3 Prostate 2.ETV1 0.65 0.71 0.00 0.87 A1.34 3.7 A2.53
TCGA.T YLAA9WH 8.8 4+3 Prostate 2.ETV1 0.80 0.65 0.00 0.90 A1.87 A3.17 2.65
TCGA.T CHA5762 8.3 4+3 Prostate 3.ETV4 0.36 0.88 0.00 0.86 0.38 3.36 A0.81
TCGA.T CHA5763 8.3 3+4 Prostate 3.ETV4 NA 0.96 0.00 0.86 1 5.75 A3.05
TCGA.T CHA5771 8.4 5+4 Prostate 3.ETV4 0.42 0.81 0.00 0.92 0.13 4.49 A2.23
TCGA.T EJA5511 9.6 4+3 Prostate 3.ETV4 0.80 0.64 0.00 0.92 2.13 0.72 A0.08
TCGA.T EJAA7NM 9.4 4+3 Prostate 3.ETV4 0.66 0.75 0.00 0.90 A2.1 A0.95 A0.79
TCGA.T G9A6371 8.5 3+3 Prostate 3.ETV4 0.27 1.12 0.00 0.88 3.39 A1.51 1.12
TCGA.T HCA7749 8.7 3+4 Prostate 3.ETV4 0.69 0.86 0.00 0.91 2.32 A1.69 0.04






cohort sample RIN Gleason Biopsy.Site Subtype TC 3' Nascent Aln% AR Stroma NE
TCGA.T HI@7168 8.5 4+4 Prostate 3.ETV4 0.58 1.06 0.00 0.89 @1.02 5.09 @2.85
TCGA.T KC@A7FD 9.3 3+3 Prostate 3.ETV4 0.80 0.64 0.00 0.91 1.05 @4.84 3.29
TCGA.T M7@A725 8.5 4+3 Prostate 3.ETV4 0.78 0.64 0.00 0.92 1.85 @5.2 2.53
TCGA.T V1@A8WV 7.8 4+5 Prostate 3.ETV4 0.52 1.00 0.00 0.84 @3.26 @0.1 @0.62
TCGA.T V1@A8X3 8.6 3+4 Prostate 3.ETV4 0.68 0.62 0.00 0.90 3.28 2.36 @0.28
TCGA.T XQ@A8TA 8.3 4+4 Prostate 3.ETV4 0.96 0.77 0.01 0.88 @3.24 @8.06 1.51
TCGA.T CH@5738 7.8 3+3 Prostate 4.FLI1 0.44 0.76 0.00 0.91 0.44 1.45 @1.57
TCGA.T H9@7775 8.7 3+3 Prostate 4.FLI1 0.80 0.82 0.00 0.91 2.72 0.44 @1.82
TCGA.T HC@7079 7.8 5+4 Prostate 4.FLI1 NA 0.88 0.00 0.85 @4.31 3.58 @2.59
TCGA.T V1@A8WN 9 3+3 Prostate 4.FLI1 0.42 0.70 0.00 0.90 2.81 3.54 @1.93
TCGA.T CH@5788 9.4 4+5 Prostate 5.SPOP 0.85 0.87 0.00 0.89 2.02 @4.64 3.1
TCGA.T EJ@5505 8.7 3+4 Prostate 5.SPOP 0.48 0.96 0.00 0.90 5.8 @1.02 0.03
TCGA.T EJ@5509 8.8 3+3 Prostate 5.SPOP 0.54 0.68 0.00 0.92 1.68 1.79 @0.5
TCGA.T EJ@5531 9 3+4 Prostate 5.SPOP 0.35 0.75 0.00 0.92 2.15 2.91 @1.13
TCGA.T EJ@7115 7.5 4+4 Prostate 5.SPOP 0.56 0.73 0.00 0.89 3.03 1.83 @0.87
TCGA.T EJ@7123 7.6 3+4 Prostate 5.SPOP 0.54 0.72 0.00 0.92 4.25 @2.76 2.34
TCGA.T EJ@7330 9.3 4+4 Prostate 5.SPOP 0.37 0.71 0.00 0.92 2.22 3.15 @2.41
TCGA.T EJ@7782 9 4+5 Prostate 5.SPOP 0.76 0.64 0.00 0.92 2.61 0.01 @0.19
TCGA.T EJ@8468 8.6 4+3 Prostate 5.SPOP 0.58 0.67 0.00 0.93 3 1.3 @0.7
TCGA.T EJ@A65E 9.1 3+3 Prostate 5.SPOP 0.62 0.88 0.00 0.88 4.23 @3.33 0.36
TCGA.T EJ@A8FS 8.1 4+3 Prostate 5.SPOP 0.82 0.80 0.00 0.87 2.18 @5.84 3.48
TCGA.T FC@7961 8.6 4+5 Prostate 5.SPOP 0.43 1.00 0.00 0.87 1.27 3.04 0.66
TCGA.T G9@6333 8.3 4+3 Prostate 5.SPOP 0.47 1.06 0.00 0.89 3.6 0.6 0.4
TCGA.T G9@7510 8.2 3+4 Prostate 5.SPOP 0.34 0.89 0.00 0.91 1.76 2.23 0.17
TCGA.T HC@7080 9 4+5 Prostate 5.SPOP 0.90 0.76 0.01 0.90 3.43 @6.23 4.03
TCGA.T HC@8258.2 7.9 3+3 Prostate 5.SPOP NA 0.97 0.00 0.90 3.03 0.36 @0.79
TCGA.T HC@8261.2 7.7 4+3 Prostate 5.SPOP 0.68 0.96 0.00 0.91 2.99 @2.24 1.51
TCGA.T J4@A6G3 7.3 4+5 Prostate 5.SPOP NA 0.87 0.00 0.92 @0.34 2.01 @1.12
TCGA.T KK@A59X 9 4+4 Prostate 5.SPOP 0.87 1.05 0.00 0.89 1.43 @2.74 3.08
TCGA.T KK@A59Z 7.2 4+3 Prostate 5.SPOP 0.83 1.13 0.00 0.89 @0.78 1.72 @0.06
TCGA.T KK@A6E0 8.6 4+4 Prostate 5.SPOP 0.64 1.04 0.00 0.92 3.39 @3.69 2.61
TCGA.T KK@A8I9 8.1 4+3 Prostate 5.SPOP 0.57 0.93 0.00 0.86 @0.33 0.1 0.88
TCGA.T KK@A8IF 8.5 4+4 Prostate 5.SPOP 0.96 1.14 0.00 0.84 0.52 @6.03 3.93
TCGA.T KK@A8IK 8.7 4+4 Prostate 5.SPOP 0.96 1.30 0.01 0.85 0.16 @8.27 4.87
TCGA.T VN@A88O 7.5 3+3 Prostate 5.SPOP 0.36 0.82 0.00 0.86 2.83 @3.1 1.05
TCGA.T VN@A88R 8.8 4+4 Prostate 5.SPOP 0.80 1.00 0.00 0.89 3.02 @3.46 2.3
TCGA.T VP@A878 8.5 4+5 Prostate 5.SPOP 0.43 0.78 0.00 0.89 1.41 2.2 @0.39
TCGA.T VP@A87B 8.2 4+4 Prostate 5.SPOP 0.91 0.79 0.00 0.80 1.43 @5.48 2.28
TCGA.T VP@A87H 8.7 4+3 Prostate 5.SPOP 0.59 0.67 0.00 0.90 2.46 @2.31 1.28
TCGA.T XJ@A83G 8.2 3+4 Prostate 5.SPOP 0.54 0.99 0.00 0.77 3.02 @4.61 3.15
TCGA.T Y6@A8TL 8.4 3+3 Prostate 5.SPOP 0.61 0.89 0.00 0.87 2.27 0.66 @0.14
TCGA.T YL@A8HM 9.5 4+4 Prostate 5.SPOP 0.87 0.81 0.00 0.90 2.95 @5.81 3.91
TCGA.T YL@A8S8 8.1 4+4 Prostate 5.SPOP 0.62 0.78 0.00 0.90 0.79 @1.21 2.03
TCGA.T YL@A8SH 7.1 3+4 Prostate 5.SPOP 0.68 0.80 0.00 0.88 1.67 0.66 0.88
TCGA.T YL@A8SO 7.9 4+3 Prostate 5.SPOP 0.56 0.91 0.01 0.89 @0.4 @1.47 1.79
TCGA.T ZG@A8QX 7.6 3+3 Prostate 5.SPOP 0.52 0.88 0.00 0.91 1.17 1.38 0.05






cohort sample RIN Gleason Biopsy.Site Subtype TC 3' Nascent Aln% AR Stroma NE
TCGA.T CH@5737 7 3+4 Prostate 6.FOXA1 0.76 0.87 0.00 0.88 3.31 @3.99 1.04
TCGA.T EJ@5494 7.7 3+4 Prostate 6.FOXA1 NA 0.74 0.00 0.92 1.15 @1.1 @2.71
TCGA.T EJ@7789 9.2 4+5 Prostate 6.FOXA1 0.96 0.72 0.00 0.90 1.35 @5.13 4.06
TCGA.T HC@7210 9.2 4+4 Prostate 6.FOXA1 0.47 0.72 0.00 0.92 3.84 2.04 @0.71
TCGA.T HC@8265.1 7.8 3+4 Prostate 6.FOXA1 0.55 1.11 0.00 0.88 @0.02 @1.57 @0.7
TCGA.T J9@A8CP 8.6 3+4 Prostate 6.FOXA1 0.60 0.86 0.00 0.85 2.42 @0.49 1.19
TCGA.T KK@A8IB 7.7 4+4 Prostate 6.FOXA1 0.43 0.94 0.00 0.89 @1.46 @1.64 2.26
TCGA.T KK@A8IG 7.6 4+4 Prostate 6.FOXA1 0.75 0.73 0.00 0.90 1.08 3.11 0.08
TCGA.T YL@A9WI 8.6 4+4 Prostate 6.FOXA1 0.89 0.80 0.00 0.90 2.86 @5.18 2.55
TCGA.T CH@5772 8.1 3+4 Prostate 7.IDH1 0.84 1.08 0.00 0.87 3.98 @2.04 @0.15
TCGA.T EJ@7125 9.4 3+3 Prostate 7.IDH1 0.69 0.64 0.00 0.92 4.45 @0.56 0.5
TCGA.T G9@7523 7.8 3+4 Prostate 7.IDH1 0.25 0.98 0.00 0.91 @2.07 7.83 @2.68
TCGA.T 2A@A8VO 7.3 3+3 Prostate 8.Other 0.56 1.03 0.00 0.85 1.19 @1.07 1.57
TCGA.T CH@5751 8.4 4+4 Prostate 8.Other 0.38 0.79 0.00 0.88 @0.1 @2.44 1.99
TCGA.T CH@5761 9.1 5+5 Prostate 8.Other 0.71 0.70 0.00 0.91 @0.7 @1.49 2.54
TCGA.T CH@5767 8.2 3+3 Prostate 8.Other 0.84 0.95 0.00 0.75 4.55 @2.54 2.79
TCGA.T CH@5792 8 3+4 Prostate 8.Other 0.40 0.73 0.00 0.92 @0.03 3.6 @0.83
TCGA.T EJ@5514 9.2 4+3 Prostate 8.Other 0.62 0.88 0.00 0.92 @2.02 0.38 0.06
TCGA.T EJ@5515 8.5 4+3 Prostate 8.Other NA 1.02 0.00 0.90 4.32 4.69 @1.96
TCGA.T EJ@5517 8.2 3+4 Prostate 8.Other 0.72 1.04 0.00 0.91 3.63 1.98 @1.63
TCGA.T EJ@5518 9.2 4+5 Prostate 8.Other 0.56 0.60 0.00 0.93 2.47 1.73 0.36
TCGA.T EJ@5532 9.1 3+4 Prostate 8.Other 0.68 0.83 0.00 0.93 4.81 @0.5 @0.52
TCGA.T EJ@7218 8.2 3+3 Prostate 8.Other 0.44 0.85 0.00 0.91 3 @3.63 1.34
TCGA.T EJ@7317 7.6 4+3 Prostate 8.Other 0.71 0.93 0.00 0.91 4.68 @1.67 0.54
TCGA.T EJ@7331 9.1 4+3 Prostate 8.Other 0.47 0.68 0.00 0.93 2.89 3.16 @1.06
TCGA.T EJ@7781 9.4 3+4 Prostate 8.Other 0.58 0.54 0.00 0.91 2.67 1.32 @1.02
TCGA.T EJ@7786 9.3 3+3 Prostate 8.Other 0.62 0.77 0.00 0.91 4.26 2.06 @0.83
TCGA.T EJ@7791 8.9 4+3 Prostate 8.Other NA 0.79 0.00 0.92 2.04 5.36 @2.97
TCGA.T EJ@7792 8.8 3+3 Prostate 8.Other 0.40 0.74 0.00 0.91 0.08 6.67 @3.58
TCGA.T EJ@7794 9.3 3+4 Prostate 8.Other 0.36 0.77 0.00 0.91 2.39 3.22 @1.81
TCGA.T EJ@8470 8.3 3+3 Prostate 8.Other 0.47 0.93 0.01 0.91 1.91 @2.06 0.48
TCGA.T EJ@A46G 9 4+3 Prostate 8.Other 0.74 1.01 0.00 0.91 1.81 @1.66 0.07
TCGA.T EJ@A46I 8.3 3+3 Prostate 8.Other 0.27 0.90 0.00 0.91 1.9 4.27 @1.15
TCGA.T EJ@A65G 8.2 3+3 Prostate 8.Other 0.51 0.95 0.00 0.89 4.05 @2.79 1.47
TCGA.T EJ@A65J 7.9 3+4 Prostate 8.Other 0.85 0.88 0.00 0.91 4.64 @5.07 2.77
TCGA.T EJ@A6RA 7.6 4+3 Prostate 8.Other NA 0.84 0.00 0.90 1.52 0.91 @0.86
TCGA.T EJ@A6RC 7.3 3+4 Prostate 8.Other NA 0.71 0.00 0.91 0.59 4.88 @1.59
TCGA.T EJ@A7NJ 9 4+5 Prostate 8.Other 0.85 0.62 0.00 0.90 3.56 0.84 @1.89
TCGA.T EJ@A8FN 8 3+3 Prostate 8.Other 0.69 0.61 0.00 0.87 1.47 1.81 @0.62
TCGA.T FC@A4JI 9.1 4+5 Prostate 8.Other 0.69 0.80 0.00 0.91 0.92 @8.31 5.21
TCGA.T FC@A5OB 8.8 4+5 Prostate 8.Other 0.86 0.90 0.00 0.90 3.61 @6.39 3.84
TCGA.T FC@A8O0 7.1 3+3 Prostate 8.Other NA 0.87 0.00 0.87 @2.06 2.78 @2.53
TCGA.T G9@6366 8.6 3+4 Prostate 8.Other 0.64 1.05 0.00 0.91 1.57 @3.54 0.71
TCGA.T G9@6367 8.1 4+3 Prostate 8.Other NA 0.90 0.00 0.90 2.34 5.63 @2.45
TCGA.T G9@6370 8 3+4 Prostate 8.Other NA 0.79 0.00 0.90 0.13 6.35 @3.84
TCGA.T G9@6378 7.2 3+4 Prostate 8.Other 0.29 1.09 0.00 0.89 @1.19 3.58 @2.71






cohort sample RIN Gleason Biopsy.Site Subtype TC 3' Nascent Aln% AR Stroma NE
TCGA.T G9@7519 7.1 3+3 Prostate 8.Other 0.28 1.18 0.00 0.91 2.11 1.52 0.48
TCGA.T G9@7521 9.2 3+4 Prostate 8.Other 0.45 0.87 0.00 0.92 2.41 @1.05 0.85
TCGA.T HC@7075 8.4 3+4 Prostate 8.Other 0.79 0.84 0.00 0.91 4.04 @5.07 2.45
TCGA.T HC@7078 8.1 4+4 Prostate 8.Other 0.74 0.98 0.00 0.89 1 @2.45 1.05
TCGA.T HC@7233 9.6 3+5 Prostate 8.Other 0.56 0.62 0.00 0.91 0.88 1.95 @0.89
TCGA.T HC@7736 9.1 3+3 Prostate 8.Other 0.60 0.55 0.00 0.92 1.35 0.82 0.12
TCGA.T HC@7737 7.5 3+4 Prostate 8.Other 0.33 0.75 0.00 0.90 3.03 1.27 0.66
TCGA.T HC@7740.1 7.9 3+4 Prostate 8.Other NA 0.73 0.00 0.91 0.79 5.21 @3.78
TCGA.T HC@7742 8.4 4+4 Prostate 8.Other 0.57 0.86 0.00 0.91 1.6 3.37 @0.59
TCGA.T HC@7750 7.7 3+3 Prostate 8.Other 0.36 0.93 0.00 0.91 0.81 5.25 @1.08
TCGA.T HC@8216 9.4 4+3 Prostate 8.Other 0.58 0.88 0.00 0.89 2.85 @1.28 0.93
TCGA.T HC@8256 9 4+3 Prostate 8.Other 0.47 0.87 0.00 0.90 3.03 @3.4 0.63
TCGA.T HC@8264 8.2 3+4 Prostate 8.Other 0.72 0.89 0.00 0.90 1.68 5.2 @0.62
TCGA.T HC@8266 7.2 4+5 Prostate 8.Other 0.31 0.90 0.00 0.90 @0.12 3.05 @2.52
TCGA.T HC@A4ZV 9.3 4+5 Prostate 8.Other 0.70 0.95 0.00 0.88 0.75 @2.29 2.66
TCGA.T HI@7170 8.3 3+3 Prostate 8.Other 0.54 0.79 0.00 0.91 @1.94 5.26 @3.13
TCGA.T J4@8200 9.3 3+4 Prostate 8.Other 0.54 0.87 0.00 0.90 2.22 2.49 @0.99
TCGA.T J9@A8CL 7.7 3+4 Prostate 8.Other 0.76 0.64 0.00 0.83 2.49 @0.55 0.93
TCGA.T J9@A8CN 7.8 3+3 Prostate 8.Other 0.88 0.86 0.00 0.84 2.68 @6.41 3.27
TCGA.T KC@A4BL 7.6 3+3 Prostate 8.Other NA 0.86 0.00 0.90 @1.87 3.84 @2.09
TCGA.T KC@A7F3 8.4 3+3 Prostate 8.Other 0.51 0.80 0.00 0.89 0.85 @0.13 1.02
TCGA.T KC@A7FA 7.7 3+4 Prostate 8.Other 0.75 0.93 0.00 0.85 @0.54 @1.91 0.75
TCGA.T KC@A7FE 8.3 3+3 Prostate 8.Other NA 0.77 0.00 0.90 @0.2 5.93 @2.56
TCGA.T KK@A6E5 7.3 3+3 Prostate 8.Other 0.62 1.07 0.00 0.90 2.56 @1.58 0.67
TCGA.T KK@A7AV 8 3+4 Prostate 8.Other 0.34 0.91 0.00 0.90 1.9 @0.77 0.25
TCGA.T KK@A8ID 7.9 4+4 Prostate 8.Other 0.51 0.73 0.00 0.89 2.07 @6.37 3.87
TCGA.T KK@A8IJ 8.6 3+3 Prostate 8.Other 0.59 0.66 0.00 0.90 2.69 @1.83 0.4
TCGA.T KK@A8IL 7.5 3+4 Prostate 8.Other 0.67 0.87 0.00 0.89 @0.92 0.12 1.19
TCGA.T M7@A721 8.5 3+4 Prostate 8.Other 0.26 0.71 0.00 0.91 2.29 0.17 1.12
TCGA.T TK@A8OK 7 5+4 Prostate 8.Other 0.54 0.68 0.00 0.85 @3.05 8.16 @4.16
TCGA.T V1@A8MF 7.8 4+4 Prostate 8.Other 0.65 0.87 0.00 0.86 0.6 @2.32 0.9
TCGA.T V1@A8MG 8.1 4+3 Prostate 8.Other 0.71 0.82 0.00 0.89 1.11 1.3 0.14
TCGA.T V1@A8ML 8.1 3+4 Prostate 8.Other 0.52 0.94 0.00 0.84 1.91 0.02 0.59
TCGA.T V1@A8MU 7.4 4+3 Prostate 8.Other 0.48 0.80 0.00 0.86 @0.06 4.26 @2.7
TCGA.T V1@A8WL 8.5 3+4 Prostate 8.Other 0.71 0.89 0.00 0.76 2.51 1.02 @1.97
TCGA.T VN@A88I 7.3 4+4 Prostate 8.Other 0.84 0.85 0.00 0.88 @3.99 8.74 @3.63
TCGA.T VN@A88N 8 4+3 Prostate 8.Other 0.76 0.77 0.00 0.87 2.84 @4.8 2.27
TCGA.T VN@A88P 8.1 3+4 Prostate 8.Other 0.81 0.85 0.00 0.86 0.71 @0.31 @0.13
TCGA.T VP@A87E 7.6 3+4 Prostate 8.Other NA 0.78 0.00 0.82 0.3 3.6 @1.98
TCGA.T WW@A8ZI 7.9 3+4 Prostate 8.Other 0.93 0.80 0.00 0.80 0.13 @5.66 1.16
TCGA.T XA@A8JR 7.1 3+3 Prostate 8.Other 0.38 0.85 0.00 0.87 1.41 1.4 0
TCGA.T XJ@A83H 8.5 3+3 Prostate 8.Other 0.53 0.82 0.00 0.81 3.01 @2.44 1.52
TCGA.T YJ@A8SW 9.5 4+4 Prostate 8.Other 0.84 0.53 0.00 0.91 3.12 @3.81 1.58
TCGA.T YL@A8HO 7.9 3+4 Prostate 8.Other 0.57 0.67 0.00 0.85 @0.14 3.5 @2.46
TCGA.T YL@A8S9 8.6 4+3 Prostate 8.Other 0.95 0.76 0.00 0.90 2.33 @10.16 5.31
TCGA.T YL@A8SB 7.6 4+3 Prostate 8.Other 0.53 0.82 0.00 0.91 0.91 2.33 @0.89






cohort sample RIN Gleason Biopsy.Site Subtype TC 3' Nascent Aln% AR Stroma NE
TCGA.T YLAA8SQ 7.8 4+3 Prostate 8.Other 0.68 0.78 0.00 0.88 3.49 A1.71 0.46
TCGA.T YLAA8SR 9 4+3 Prostate 8.Other 0.68 0.75 0.00 0.91 3.55 A0.88 2.24
TCGA.T YLAA9WJ 8.9 3+3 Prostate 8.Other 0.42 0.61 0.00 0.88 2.11 0.56 A0.62
TCGA.T ZGAA8QW 8 3+4 Prostate 8.Other 0.41 0.87 0.00 0.88 A1.15 1.45 A0.29
TCGA.N CHA5761 7.3 NA Prostate 9.Normal 0.00 0.76 0.00 0.91 0.14 3.01 A2.07
TCGA.N CHA5767 8.9 NA Prostate 9.Normal 0.00 0.95 0.00 0.92 A1.83 5.03 A2.12
TCGA.N CHA5768 7.5 NA Prostate 9.Normal 0.00 0.89 0.00 0.88 0.91 3.66 A3.35
TCGA.N CHA5769 7.1 NA Prostate 9.Normal 0.00 0.81 0.00 0.89 A1.3 0.41 1.18
TCGA.N EJA7115 8.8 NA Prostate 9.Normal 0.00 0.75 0.00 0.91 1.53 5.88 A2.6
TCGA.N EJA7123 8.7 NA Prostate 9.Normal 0.00 0.70 0.01 0.91 A3.69 13.32 A5.27
TCGA.N EJA7125 8.3 NA Prostate 9.Normal 0.00 0.78 0.00 0.90 0.57 3.8 A2.41
TCGA.N EJA7314 9 NA Prostate 9.Normal 0.00 0.64 0.00 0.92 0.73 8.98 A4.77
TCGA.N EJA7315 9.6 NA Prostate 9.Normal 0.00 0.67 0.00 0.92 A2.64 9.33 A5.25
TCGA.N EJA7317 9.5 NA Prostate 9.Normal 0.00 0.64 0.00 0.93 3.95 4.65 A2.67
TCGA.N EJA7321 8.8 NA Prostate 9.Normal 0.00 0.70 0.00 0.92 1.67 5.76 A3.94
TCGA.N EJA7327 9.6 NA Prostate 9.Normal 0.00 0.81 0.00 0.90 4.23 A0.1 A1.41
TCGA.N EJA7328 8.2 NA Prostate 9.Normal 0.00 0.68 0.00 0.91 A2.64 11.89 A5.66
TCGA.N EJA7330 8.2 NA Prostate 9.Normal 0.00 0.64 0.00 0.92 A3.56 9.63 A5.95
TCGA.N EJA7331 9.2 NA Prostate 9.Normal 0.00 0.74 0.00 0.91 0.87 8.36 A4.63
TCGA.N EJA7781 8.5 NA Prostate 9.Normal 0.00 0.75 0.00 0.92 A3.11 12.3 A6.35
TCGA.N EJA7782 8.8 NA Prostate 9.Normal 0.00 0.67 0.00 0.90 0.93 3.19 A2.22
TCGA.N EJA7783 8 NA Prostate 9.Normal 0.00 0.77 0.00 0.92 A5.65 13.68 A5.15
TCGA.N EJA7784 8.8 NA Prostate 9.Normal 0.00 0.70 0.00 0.92 0.77 6.04 A4.97
TCGA.N EJA7785 8.5 NA Prostate 9.Normal 0.00 0.67 0.00 0.91 0.42 8.31 A4.51
TCGA.N EJA7786 8.6 NA Prostate 9.Normal 0.00 0.66 0.00 0.88 A0.84 9.96 A5.69
TCGA.N EJA7789 8.6 NA Prostate 9.Normal 0.00 0.69 0.00 0.90 1.39 4.65 A3.2
TCGA.N EJA7792 8.8 NA Prostate 9.Normal 0.00 0.76 0.00 0.91 A0.52 7.72 A4.96
TCGA.N EJA7793 8.7 NA Prostate 9.Normal 0.00 0.78 0.00 0.92 1.37 8.26 A4.54
TCGA.N EJA7794 9.1 NA Prostate 9.Normal 0.00 0.61 0.00 0.91 A1.97 8.11 A5.8
TCGA.N EJA7797 8.5 NA Prostate 9.Normal 0.00 0.84 0.00 0.92 0.73 7.76 A4.6
TCGA.N EJAA8FO 8.4 NA Prostate 9.Normal 0.00 0.63 0.00 0.90 A3.53 10.96 A6.08
TCGA.N G9A6333 7.4 NA Prostate 9.Normal 0.00 1.10 0.00 0.90 A3.96 7.3 A3.93
TCGA.N G9A6342 7.4 NA Prostate 9.Normal 0.00 1.19 0.00 0.89 1.77 2.87 A1.68
TCGA.N G9A6348 7 NA Prostate 9.Normal 0.00 1.21 0.00 0.89 A3 8.44 A4.3
TCGA.N G9A6351 7.5 NA Prostate 9.Normal 0.00 1.05 0.00 0.90 1.53 6.17 A3.36
TCGA.N G9A6356 7.6 NA Prostate 9.Normal 0.00 1.04 0.00 0.89 0.38 A2.18 A2.28
TCGA.N G9A6362 7.5 NA Prostate 9.Normal 0.00 1.57 0.00 0.87 0.74 A0.86 A0.11
TCGA.N G9A6363 7.5 NA Prostate 9.Normal 0.00 0.90 0.00 0.89 A0.58 4.16 A2.7
TCGA.N G9A6365 7.2 NA Prostate 9.Normal 0.00 1.14 0.00 0.89 A1.21 2.94 A1.63
TCGA.N G9A6384 7 NA Prostate 9.Normal 0.00 1.02 0.00 0.90 0.16 7.32 A2.63
TCGA.N G9A6496 7.5 NA Prostate 9.Normal 0.00 1.12 0.00 0.90 A1.7 7.84 A3.57
TCGA.N G9A6499 7.6 NA Prostate 9.Normal 0.00 1.14 0.00 0.88 A0.87 5.34 A0.15
TCGA.N HCA7211 8.2 NA Prostate 9.Normal 0.00 0.86 0.00 0.91 A5.95 0.31 A1.04
TCGA.N HCA7737 8.1 NA Prostate 9.Normal 0.00 0.81 0.00 0.91 A5.44 5.58 A3.17
TCGA.N HCA7738 7.4 NA Prostate 9.Normal 0.00 0.84 0.00 0.89 A6.05 6.2 A3.21
TCGA.N HCA7740 8.1 NA Prostate 9.Normal 0.00 0.88 0.00 0.91 A6.07 4 A3.22






cohort sample RIN Gleason Biopsy.Site Subtype TC 3' Nascent Aln% AR Stroma NE
TCGA.N HC@7745 7.1 NA Prostate 9.Normal 0.00 0.74 0.00 0.92 @6.18 8.93 @4.2
TCGA.N HC@7747 7.6 NA Prostate 9.Normal 0.00 0.77 0.00 0.92 @6.07 3 @2.3
TCGA.N HC@7752 7.6 NA Prostate 9.Normal 0.00 1.00 0.00 0.90 @2.6 7.63 @3.84
TCGA.N HC@7819 7.8 NA Prostate 9.Normal 0.00 0.81 0.00 0.91 1.48 5.36 @3.6
TCGA.N HC@8258 7.5 NA Prostate 9.Normal 0.00 0.82 0.00 0.92 @6.11 0.61 @1.57
TCGA.N HC@8259 7.2 NA Prostate 9.Normal 0.00 0.93 0.00 0.91 1.83 5.54 @2.75
TCGA.N HC@8260 8.2 NA Prostate 9.Normal 0.00 0.85 0.00 0.91 2.96 4.62 @3.3
TCGA.N HC@8262 7.9 NA Prostate 9.Normal 0.00 0.78 0.00 0.91 @2.28 4.41 @3.85
TCGA.N J4@A83J 8.1 NA Prostate 9.Normal 0.00 0.67 0.01 0.90 @0.42 4.37 @3.4
Michigan.T UT_4001 8.9 3+4 Prostate 1.ERG 0.70 0.51 0.00 0.91 @0.55 @3.7 1.77
Michigan.T UT_4003 9.4 3+3 Prostate 1.ERG 0.47 0.38 0.00 0.92 0.79 0.67 @0.68
Michigan.T UT_4006 8.8 3+3 Prostate 1.ERG 0.64 0.36 0.00 0.95 @1.59 @4.06 1.28
Michigan.T UT_4008 9.5 3+4 Prostate 1.ERG 0.70 0.50 0.00 0.96 2.48 @2.26 2.05
Michigan.T UT_4016 9.7 3+3 Prostate 1.ERG 0.21 0.52 0.00 0.96 0.26 3.9 @2.73
Michigan.T UT_4019 9.5 4+3 Prostate 1.ERG 0.56 0.49 0.00 0.95 0.22 1.82 @0.44
Michigan.T UT_4022 9.6 3+4 Prostate 1.ERG 0.61 0.59 0.01 0.95 0.61 @1.29 0.92
Michigan.T UT_4023 9.6 3+3 Prostate 1.ERG 0.40 0.57 0.00 0.95 1.6 1.74 0.06
Michigan.T UT_4025 9.2 3+3 Prostate 1.ERG NA 0.60 0.01 0.95 @0.33 5.14 @2.4
Michigan.T UT_4028 9.4 3+4 Prostate 1.ERG 0.59 0.54 0.01 0.95 3.36 @1.59 1.78
Michigan.T UT_4028 9.2 3+4 Prostate 1.ERG 0.48 0.64 0.01 0.94 0.86 0.53 @1.06
Michigan.T UT_4034 9.3 4+4 Prostate 1.ERG 0.26 0.61 0.01 0.95 @0.49 3.45 @1.96
Michigan.T UT_4002 9.1 3+3 Prostate 2.ETV1 0.70 0.41 0.00 0.91 2.49 @3.43 1.33
Michigan.T UT_4010 9.8 3+3 Prostate 4.FLI1 0.48 0.55 0.01 0.95 1.55 0.51 0.69
Michigan.T UT_4030 9.6 4+3 Prostate 5.SPOP 0.82 0.46 0.00 0.95 3.33 @8.2 4.39
Michigan.T UT_4009 9.2 3+4 Prostate 6.FOXA1 0.58 0.64 0.01 0.95 1.96 @1.1 1.19
Michigan.T UT_4017 9.5 3+4 Prostate 6.FOXA1 0.64 0.43 0.01 0.96 2.67 @3.6 1.8
Michigan.T UT_4018 9.2 3+3 Prostate 6.FOXA1 0.32 0.67 0.01 0.96 1.29 1.91 0.32
Michigan.T UT_4018 9.2 3+3 Prostate 6.FOXA1 0.32 0.78 0.01 0.94 1.59 1.99 0.07
Michigan.T UT_4032 7.3 4+3 Prostate 6.FOXA1 0.70 0.84 0.00 0.91 1.95 @4.27 2.76
Michigan.T UT_4005 9.3 4+3 Prostate 8.Other 0.53 0.45 0.00 0.91 1.51 @3.48 1.35
Michigan.T UT_4006 8.8 NA Prostate 8.Other 0.25 0.46 0.00 0.92 @2.64 @2.23 0.63
Michigan.T UT_4007 9.4 NA Prostate 8.Other 0.38 0.21 0.00 0.93 4.21 @0.4 1.03
Michigan.T UT_4011 9.8 3+3 Prostate 8.Other 0.33 0.51 0.00 0.96 2.48 2.55 @0.9
Michigan.T UT_4012 9.5 3+3 Prostate 8.Other 0.26 0.45 0.01 0.95 2.56 0.96 @1.13
Michigan.T UT_4013 8.9 3+3 Prostate 8.Other 0.35 0.59 0.00 0.95 3.43 @4.42 2.32
Michigan.T UT_4014 9.1 NA Prostate 8.Other 0.29 0.61 0.01 0.95 2.15 2.45 @2.25
Michigan.T UT_4015 8 3+3 Prostate 8.Other 0.46 0.58 0.01 0.94 @1.63 2.89 @0.88
Michigan.T UT_4015 9.3 3+3 Prostate 8.Other 0.51 0.54 0.00 0.95 @0.9 7.09 @3
Michigan.T UT_4015 9.6 NA Prostate 8.Other 0.26 0.58 0.01 0.95 2.59 1.66 @1.67
Michigan.T UT_4020 9.5 3+3 Prostate 8.Other 0.40 0.66 0.00 0.95 1.92 @0.01 0.7
Michigan.T UT_4021 9.7 3+3 Prostate 8.Other 0.67 0.42 0.00 0.96 1.88 @1.23 2.13
Michigan.T UT_4024 7.3 3+3 Prostate 8.Other 0.67 0.49 0.00 0.96 2.46 @2.67 2.01
Michigan.T UT_4027 9.2 3+4 Prostate 8.Other NA 0.61 0.00 0.94 3.8 @3.34 @0.31
Michigan.T UT_4029 8.2 4+3 Prostate 8.Other 0.54 0.54 0.00 0.94 @0.31 7.41 @1.74
Michigan.T UT_4031 8.5 3+4 Prostate 8.Other 0.58 0.71 0.00 0.93 @1.46 4.99 @1.47
Michigan.T UT_4035 6.1 3+4 Prostate 8.Other 0.70 0.73 0.01 0.82 @2.74 @6.23 1.41






cohort sample RIN Gleason Biopsy.Site Subtype TC 3' Nascent Aln% AR Stroma NE
Michigan.N UT_4002 8.4 NA Prostate 9.Normal 0.00 0.40 0.00 0.92 0.73 7.37 J4.08
Michigan.N UT_4003 9.4 NA Prostate 9.Normal 0.00 0.37 0.00 0.92 0.33 6.7 J2.62
Michigan.N UT_4004 8.4 NA Prostate 9.Normal 0.00 0.58 0.00 0.92 1.15 4.14 J1.52
Michigan.N UT_4005 9.4 NA Prostate 9.Normal 0.00 0.71 0.00 0.88 J3 6.85 J3.72
Michigan.N UT_4006 9.2 NA Prostate 9.Normal 0.00 0.51 0.00 0.89 1.5 3.35 J0.98
Michigan.N UT_4007 9 NA Prostate 9.Normal 0.00 0.47 0.00 0.93 1.28 2.15 J1.37
Michigan.N UT_4008 9.3 NA Prostate 9.Normal 0.00 0.59 0.01 0.96 J2.67 8.46 J3.39
Michigan.N UT_4008 8.8 NA Prostate 9.Normal 0.00 0.47 0.00 0.96 J5.53 12.72 J4.9
Michigan.N UT_4009 9.6 NA Prostate 9.Normal 0.00 0.61 0.01 0.96 J0.84 8.41 J4.6
Michigan.N UT_4009 9.5 NA Prostate 9.Normal 0.00 0.47 0.00 0.96 J1.52 7.95 J4.99
Michigan.N UT_4010 9.4 NA Prostate 9.Normal 0.00 0.42 0.00 0.97 J4.5 13.4 J4.36
Michigan.N UT_4010 9.3 NA Prostate 9.Normal 0.00 0.43 0.00 0.96 J1.11 8.69 J3.72
Michigan.N UT_4011 8.2 NA Prostate 9.Normal 0.00 0.39 0.01 0.96 J0.8 7.67 J4.22
Michigan.N UT_4011 9.6 NA Prostate 9.Normal 0.00 0.46 0.00 0.96 1.5 4.07 J0.61
Michigan.N UT_4012 8.9 NA Prostate 9.Normal 0.00 0.54 0.01 0.95 1.59 4.66 J1.68
Michigan.N UT_4013 9.7 NA Prostate 9.Normal 0.00 0.52 0.01 0.95 J1.72 7.63 J2.66
Michigan.N UT_4014 8.3 NA Prostate 9.Normal 0.00 0.46 0.00 0.96 J6.5 13.51 J5
Michigan.N UT_4015 9.4 NA Prostate 9.Normal 0.00 0.50 0.00 0.96 0.57 5.99 J2.42
Michigan.N UT_4016 9.2 NA Prostate 9.Normal 0.00 0.52 0.00 0.96 J0.4 6.75 J2.49
Michigan.N UT_4017 8 NA Prostate 9.Normal 0.00 0.49 0.01 0.96 0.96 6.06 J3.3
Michigan.N UT_4018 9.2 NA Prostate 9.Normal 0.00 0.56 0.00 0.96 1.32 5.97 J3.41
Michigan.N UT_4019 9.3 NA Prostate 9.Normal 0.00 0.61 0.00 0.96 J2.23 6.08 J2.91
Michigan.N UT_4019 8.4 NA Prostate 9.Normal 0.00 0.46 0.01 0.96 J3.71 6.63 J3.07
Michigan.N UT_4020 9.5 NA Prostate 9.Normal 0.00 0.44 0.00 0.96 1.21 7.42 J3.18
Michigan.N UT_4020 9.7 NA Prostate 9.Normal 0.00 0.44 0.00 0.96 3.09 4.78 J2.03
Michigan.N UT_4021 9.6 NA Prostate 9.Normal 0.00 0.56 0.00 0.96 1.73 4.63 J2.77
Michigan.N UT_4021 9.3 NA Prostate 9.Normal 0.00 0.45 0.00 0.95 0.84 5.57 J3.59
Michigan.N UT_4022 9.1 NA Prostate 9.Normal 0.00 0.52 0.00 0.96 J1.74 8.51 J3.85
Michigan.N UT_4022 9.7 NA Prostate 9.Normal 0.00 0.55 0.00 0.96 1.89 J0.05 0.1
Michigan.N UT_4023 9.5 NA Prostate 9.Normal 0.00 0.52 0.00 0.96 0.03 7.14 J3.71
Michigan.N UT_4023 9.6 NA Prostate 9.Normal 0.00 0.49 0.00 0.96 J0.09 8.73 J3.45
Michigan.N UT_4024 9.5 NA Prostate 9.Normal 0.00 0.45 0.01 0.97 2.31 4.13 J2.38
Michigan.N UT_4024 9.3 NA Prostate 9.Normal 0.00 0.49 0.00 0.96 2.52 2.04 J1.73
Michigan.N UT_4025 9.1 NA Prostate 9.Normal 0.00 0.51 0.01 0.96 J0.19 8.79 J3.63
Michigan.N UT_4025 9.3 NA Prostate 9.Normal 0.00 0.53 0.01 0.95 J0.52 3.64 J2.47
Michigan.N UT_4026 8.9 NA Prostate 9.Normal 0.00 0.55 0.01 0.95 J1.42 9.22 J4.33
Michigan.N UT_4026 8.6 NA Prostate 9.Normal 0.00 0.51 0.00 0.96 J3.22 12.3 J5.09
Michigan.N UT_4027 9.6 NA Prostate 9.Normal 0.00 0.52 0.00 0.96 1.71 5.94 J3.08
Michigan.N UT_4027 9.2 NA Prostate 9.Normal 0.00 0.54 0.00 0.95 3.23 2.71 J0.92
Michigan.N UT_4028 7 NA Prostate 9.Normal 0.00 0.40 0.00 0.95 3.69 J2.45 2.59
Michigan.N UT_4028 8.8 NA Prostate 9.Normal 0.00 0.46 0.00 0.95 J1.66 10 J4.36
Michigan.N UT_4029 7.9 NA Prostate 9.Normal 0.00 0.61 0.01 0.94 J2.05 3.04 J0.97
Michigan.N UT_4029 9 NA Prostate 9.Normal 0.00 0.61 0.00 0.95 0 4.98 J2.18
Michigan.N UT_4030 9 NA Prostate 9.Normal 0.00 0.54 0.00 0.95 2.08 3.44 J1.05
Michigan.N UT_4030 9 NA Prostate 9.Normal 0.00 0.52 0.00 0.95 J0.83 9.17 J3.85
Michigan.N UT_4031 8.6 NA Prostate 9.Normal 0.00 0.67 0.00 0.95 J3.26 10.41 J4.17






cohort sample RIN Gleason Biopsy.Site Subtype TC 3' Nascent Aln% AR Stroma NE
Michigan.N UT_4032 9.4 NA Prostate 9.Normal 0.00 0.50 0.00 0.95 I1.68 10.12 I4.15
Michigan.N UT_4032 8.9 NA Prostate 9.Normal 0.00 0.53 0.00 0.95 I1.78 8.84 I3.55
Michigan.N UT_4033 9.6 NA Prostate 9.Normal 0.00 0.46 0.00 0.95 1.2 1.21 I0.06
Michigan.N UT_4033 7.3 NA Prostate 9.Normal 0.00 0.49 0.00 0.87 I7.02 14.66 I3.34
Michigan.N UT_4034 9.1 NA Prostate 9.Normal 0.00 0.63 0.01 0.95 0.49 6.53 I2.93
Michigan.N UT_4034 8.9 NA Prostate 9.Normal 0.00 0.51 0.00 0.94 I1.99 10.67 I5.73
Michigan.N UT_4035 9.1 NA Prostate 9.Normal 0.00 0.84 0.02 0.91 I3.82 5.67 I3.03
Michigan.N UT_4035 7.9 NA Prostate 9.Normal 0.00 0.76 0.01 0.92 I3.22 4.54 I2.35
SU2C MO_1015 4.9 NA Lymph_Node 1.ERG 0.66 1.88 0.02 0.73 I6.26 I4.48 1.12
SU2C MO_1040 6.8 NA Lymph_Node 1.ERG 0.70 0.79 0.01 0.89 2.85 I4.48 1.73
SU2C MO_1071 7.4 NA Prostate 1.ERG 0.33 0.82 0.01 0.92 I4.38 3.92 I2.22
SU2C MO_1084 5.7 NA Lymph_Node 1.ERG 0.81 1.29 0.02 0.82 I5.08 I13.83 5.55
SU2C MO_1095 2.5 NA Soft_Tissue 1.ERG 0.40 0.68 0.01 0.87 I5.6 I8.6 3.22
SU2C MO_1114 9.8 NA Lymph_Node 1.ERG 0.88 0.80 0.00 0.91 0.43 I6.72 3.86
SU2C MO_1118 10 NA Liver 1.ERG 0.91 0.56 0.00 0.91 I6.74 I4.59 I4.92
SU2C MO_1124 9.3 NA Soft_Tissue 1.ERG 0.95 0.54 0.01 0.94 I6.17 I5.95 1.51
SU2C MO_1161 9.7 NA Liver 1.ERG 0.82 0.73 0.01 0.92 I4.09 I6.18 I0.02
SU2C MO_1176 8.3 NA Lymph_Node 1.ERG 0.86 0.70 0.01 0.92 I1.78 I6.79 3.08
SU2C MO_1179 5.9 NA Bone 1.ERG 0.30 0.88 0.01 0.91 I6.64 I6.73 3.38
SU2C MO_1192 9.9 NA Lymph_Node 1.ERG 0.68 0.51 0.00 0.93 3.53 I4.25 2.45
SU2C MO_1202 9.7 NA Liver 1.ERG 0.47 0.59 0.01 0.92 I3.37 I3.02 1.95
SU2C MO_1215 9.8 NA Soft_Tissue 1.ERG 0.88 0.52 0.00 0.93 I7.38 I2.4 I5.37
SU2C MO_1241 9.5 NA Liver 1.ERG 0.82 0.51 0.01 0.93 I3.78 I6.62 2.12
SU2C MO_1244 9.3 NA Liver 1.ERG 0.94 0.56 0.01 0.93 I2.29 I6.97 5.44
SU2C MO_1249 10 NA Lymph_Node 1.ERG 0.48 0.60 0.01 0.92 I3 I6.97 3.46
SU2C MO_1277 9.8 NA Bone 1.ERG 0.87 0.71 0.00 0.94 0.93 I6.71 5.15
SU2C MO_1316 NA NA Lymph_Node 1.ERG 0.85 0.63 0.01 0.90 0.09 I6.83 3.36
SU2C MO_1337 9.6 NA Liver 1.ERG 0.84 0.46 0.00 0.92 I3.47 I4.04 2.95
SU2C SC_9009 7.3 NA Lymph_Node 1.ERG 0.86 1.26 0.03 0.89 I3.22 I7.66 4.11
SU2C SC_9016 9.9 NA Lymph_Node 1.ERG 0.32 1.66 0.02 0.87 I2.74 I6.56 3.06
SU2C SC_9017 9.9 NA Liver 1.ERG 0.74 0.82 0.01 0.90 I6.1 I2.78 1.64
SU2C SC_9018 8.6 NA Bone 1.ERG 0.55 0.82 0.00 0.92 I0.79 I8.66 3.54
SU2C SC_9022 10 NA Soft_Tissue 1.ERG 0.55 0.64 0.01 0.94 I3.98 I1.29 0.74
SU2C SC_9026 6.9 NA Bone 1.ERG 0.39 1.18 0.00 0.82 I3.57 I7.23 3.03
SU2C SC_9034 4.2 NA Bone 1.ERG 0.30 0.77 0.01 0.86 I5.98 I3.37 2.28
SU2C SC_9035 9.6 NA Lymph_Node 1.ERG 0.63 0.43 0.01 0.94 I1.55 I6.37 3.53
SU2C SC_9037 9.1 NA Liver 1.ERG 0.30 0.72 0.00 0.88 I5.67 I6.02 1.42
SU2C SC_9043 9.3 NA Bone 1.ERG 0.75 0.82 0.01 0.89 I0.55 I5.69 3.67
SU2C SC_9046 8 NA Liver 1.ERG 0.30 1.06 0.00 0.86 I1.85 I6.09 2.62
SU2C SC_9049 8 NA Bone 1.ERG 0.30 0.65 0.00 0.89 I4.5 I3.53 2.72
SU2C SC_9050 8.2 NA Lymph_Node 1.ERG 0.75 1.19 0.01 0.90 I4.49 I9.13 3.62
SU2C SC_9056 10 NA Bone 1.ERG 0.45 0.44 0.00 0.95 0.23 I8.04 2.45
SU2C SC_9059 8.7 NA Lymph_Node 1.ERG 0.82 0.60 0.00 0.93 I2.01 I5.44 I0.84
SU2C SC_9060 9.3 NA Liver 1.ERG 0.41 0.57 0.00 0.93 I6.18 I1.21 0.56
SU2C SC_9061 8.9 NA Bone 1.ERG 0.65 0.53 0.00 0.94 0.28 I4.57 4.37
SU2C SC_9063 9.6 NA Lymph_Node 1.ERG 0.60 0.53 0.00 0.94 I2.78 I4.25 0.87






cohort sample RIN Gleason Biopsy.Site Subtype TC 3' Nascent Aln% AR Stroma NE
SU2C SC_9071 7.6 NA Bone 1.ERG 0.30 1.15 0.00 0.90 H6.76 H5.81 3.16
SU2C SC_9086 6.8 NA Bone 1.ERG 0.42 0.79 0.01 0.91 H2.11 H3.48 3.02
SU2C SC_9092 NA NA Bone 1.ERG 0.75 0.31 0.01 0.94 H1.08 H3.28 2.78
SU2C SC_9097 9.6 NA Lymph_Node 1.ERG 0.82 0.28 0.00 0.95 H0.42 H6.02 5.45
SU2C SC_9099 9.6 NA Lymph_Node 1.ERG 0.86 0.42 0.01 0.93 1.68 H6.5 3.16
SU2C SC_9104 8.8 NA Lymph_Node 1.ERG 0.65 0.47 0.00 0.93 H1.86 H6.47 3.18
SU2C SC_9107 9.7 NA Liver 1.ERG 0.60 0.56 0.01 0.93 H3.48 H5.44 3.17
SU2C SC_9109 9.8 NA Lymph_Node 1.ERG 0.51 0.24 0.00 0.94 2.45 H5.18 3.5
SU2C 1115154 NA NA Lymph_Node 1.ERG 0.80 0.18 0.00 0.89 0.1 H4.74 4.03
SU2C 1115156 NA NA Lymph_Node 1.ERG 0.69 0.32 0.00 0.89 1.03 H1.95 1.03
SU2C 1115157 NA NA Lymph_Node 1.ERG 0.38 0.29 0.00 0.89 H1.89 H1.04 0.9
SU2C 1115183 NA NA Bone 1.ERG 0.64 0.23 0.00 0.78 0.79 H3.16 2.98
SU2C 1115244 NA NA Bone 1.ERG 0.50 0.38 0.01 0.80 H1.37 H2.56 2.07
SU2C 6115117 NA NA Soft_Tissue 1.ERG 0.52 0.67 0.01 0.87 H4.61 H3.31 3.41
SU2C 6115121 NA NA Soft_Tissue 1.ERG 0.67 1.38 0.02 0.86 H4.5 H9.14 4.06
SU2C 6115122 NA NA Lymph_Node 1.ERG 0.56 0.56 0.00 0.85 H5.42 2.24 0.55
SU2C 6115219 NA NA Lymph_Node 1.ERG 0.74 0.66 0.01 0.81 1.09 H5.45 2.5
SU2C 6115234 NA NA Lymph_Node 1.ERG 0.32 0.64 0.01 0.83 H1.11 H4.96 4.17
SU2C 6115247.1 NA NA Lymph_Node 1.ERG 0.80 0.72 0.01 0.82 H0.25 H4.17 2.25
SU2C TP_2001 8.7 NA Lymph_Node 1.ERG 0.50 0.91 0.01 0.91 H0.38 H5.44 2.3
SU2C TP_2034 7.6 NA Bone 1.ERG 0.51 0.57 0.01 0.90 H6.63 6.55 H3.37
SU2C TP_2054 9 NA Lymph_Node 1.ERG 0.45 0.45 0.00 0.92 H3.05 H1.5 2.26
SU2C MO_1221 6.6 NA Bone 2.ETV1 0.79 0.82 0.00 0.89 H2.25 H4.85 3.41
SU2C SC_9019 9.4 NA Bone 2.ETV1 0.42 0.66 0.01 0.91 H2.7 H2.52 2.35
SU2C SC_9027 7.9 NA Bone 2.ETV1 0.44 0.45 0.00 0.95 H2.3 H7.1 3.35
SU2C SC_9028 6.3 NA Prostate 2.ETV1 0.30 0.85 0.01 0.90 H7.59 H5.47 4.03
SU2C SC_9055 9.6 NA Lymph_Node 2.ETV1 0.33 0.60 0.00 0.93 H0.85 H3.26 2.44
SU2C SC_9057 8.5 NA Soft_Tissue 2.ETV1 0.72 0.56 0.00 0.94 H2.85 H4.96 2.38
SU2C SC_9072 10 NA Bone 2.ETV1 0.45 0.41 0.00 0.93 0.94 H8.6 4.11
SU2C 6115114 NA NA Soft_Tissue 2.ETV1 0.89 0.78 0.00 0.79 H2.24 H10.39 5.15
SU2C 6115118 NA NA Soft_Tissue 2.ETV1 0.54 0.47 0.00 0.87 H0.68 H1.83 2.81
SU2C MO_1012 NA NA Soft_Tissue 3.ETV4 0.53 2.54 0.01 0.36 H8.94 H3.6 1.37
SU2C MO_1054 7.4 NA Prostate 3.ETV4 0.30 0.63 0.01 0.91 H2.97 H2.27 1.23
SU2C MO_1232 7.6 NA Soft_Tissue 3.ETV4 0.58 0.59 0.00 0.94 H5.63 H0.83 1.18
SU2C MO_1262 10 NA Lymph_Node 3.ETV4 0.83 0.53 0.01 0.94 1.37 H7.38 4.5
SU2C SC_9001 7 NA Liver 3.ETV4 0.70 1.22 0.01 0.80 H6.58 1.09 H4.2
SU2C SC_9065 7 NA Bone 3.ETV4 0.63 0.69 0.00 0.84 H3.65 H9.87 4.79
SU2C SC_9093 9.5 NA Soft_Tissue 3.ETV4 0.72 0.76 0.00 0.92 H2.39 H8.11 5.19
SU2C 1115153 NA NA Bone 3.ETV4 0.34 0.10 0.00 0.87 H1.07 H2.24 2.93
SU2C 6115115 NA NA Lymph_Node 3.ETV4 0.40 0.68 0.00 0.85 H1.97 H8.34 4.65
SU2C 6115224 NA NA Soft_Tissue 3.ETV4 0.70 0.30 0.01 0.83 H1.79 H6.67 4.38
SU2C 6115237 NA NA Liver 3.ETV4 0.77 0.50 0.01 0.83 H6.98 H5.58 H2.51
SU2C TP_2009 4.8 NA Bone 3.ETV4 0.45 1.11 0.01 0.82 H5.38 H2.14 2.24
SU2C TP_2020 7.6 NA Bone 3.ETV4 0.42 1.23 0.00 0.85 H4.21 H6.45 3.47
SU2C SC_9007 9.2 NA Lymph_Node 4.FLI1 0.52 0.79 0.00 0.82 H1.25 1.37 0.98
SU2C MO_1074 NA NA Bone 5.SPOP 0.43 0.76 0.01 0.92 H4.45 H0.97 1.85





cohort sample RIN Gleason Biopsy.Site Subtype TC 3' Nascent Aln% AR Stroma NE
SU2C MO_1336 4.3 NA Bone 5.SPOP 0.59 0.90 0.00 0.87 M1.32 M5.82 3.69
SU2C SC_9008 7.9 NA Liver 5.SPOP 0.92 0.72 0.01 0.89 0.05 M6.51 5.01
SU2C SC_9094 6.6 NA Bone 5.SPOP 0.55 0.41 0.00 0.89 M3.73 M5.91 3.78
SU2C SC_9100 7 NA Bone 5.SPOP 0.20 0.55 0.00 0.87 M4.43 M4.68 4.01
SU2C SC_9103 9.4 NA Bone 5.SPOP 0.74 0.36 0.00 0.94 M3.91 M6.36 4.32
SU2C TP_2060 9.2 NA Lymph_Node 5.SPOP 0.30 1.17 0.01 0.83 M3.38 M3.09 2.83
SU2C SC_9029 9.9 NA Soft_Tissue 6.FOXA1 0.98 0.57 0.00 0.92 0.83 M12.11 6.16
SU2C SC_9038 9.7 NA Lymph_Node 6.FOXA1 0.58 0.82 0.00 0.93 M4.07 0.11 2.37
SU2C SC_9047 8 NA Bone 6.FOXA1 0.65 0.80 0.00 0.87 M2.24 M6.76 4.81
SU2C SC_9048 8 NA Bone 6.FOXA1 0.33 0.55 0.00 0.90 M3.72 M3.86 2.77
SU2C SC_9058 9.7 NA Lymph_Node 6.FOXA1 0.73 0.54 0.00 0.93 M1.47 M4.68 2.61
SU2C SC_9091 7.9 NA Bone 6.FOXA1 0.63 0.87 0.00 0.75 M3.5 M10.9 5.2
SU2C 1115161 NA NA Lymph_Node 6.FOXA1 0.87 0.33 0.00 0.81 2.15 M6.29 4.94
SU2C MO_1013 6.1 NA Lymph_Node 8.Other 0.42 1.41 0.02 0.90 M3.66 M3.2 3.81
SU2C MO_1014 NA NA Lymph_Node 8.Other 0.62 1.72 0.01 0.83 M4.23 M5.64 4.74
SU2C MO_1020 8 NA Liver 8.Other 0.36 0.90 0.01 0.88 M6.39 0.33 M0.9
SU2C MO_1094 9.7 NA Bone 8.Other 0.85 1.64 0.02 0.91 M7.15 M2.33 0.61
SU2C MO_1184 9.2 NA Liver 8.Other 0.56 0.87 0.00 0.90 M3.36 M0.95 1.12
SU2C MO_1219 8 NA Bone 8.Other 0.30 0.94 0.00 0.73 M4.99 M11.19 4.55
SU2C MO_1339 10 NA Lymph_Node 8.Other 0.79 0.37 0.00 0.93 M1.24 M1.98 M0.44
SU2C SC_9010 7.3 NA Lymph_Node 8.Other 0.61 0.70 0.01 0.88 M2.94 M6.12 4.13
SU2C SC_9012 9.6 NA Liver 8.Other 0.32 1.12 0.00 0.89 M6.7 M5.8 2.48
SU2C SC_9023 6 NA Bone 8.Other 0.67 0.92 0.01 0.89 M5.93 M6.76 2.92
SU2C SC_9030 10 NA Soft_Tissue 8.Other 0.91 0.67 0.00 0.90 1.16 M9.76 5.56
SU2C SC_9031 9.8 NA Liver 8.Other 0.67 0.65 0.01 0.91 M6.93 1.1 M6.99
SU2C SC_9032 10 NA Lymph_Node 8.Other 0.87 0.80 0.01 0.90 M0.12 M11.08 6.25
SU2C SC_9036 10 NA Lymph_Node 8.Other 0.46 0.49 0.00 0.90 1.63 M3.91 2.96
SU2C SC_9054 9.9 NA Lymph_Node 8.Other 0.66 0.59 0.00 0.92 M1.12 M8.12 1.41
SU2C SC_9062 9.5 NA Lymph_Node 8.Other 0.74 0.59 0.00 0.94 M5.5 M2.44 3.29
SU2C SC_9073 8.8 NA Lymph_Node 8.Other 0.38 0.52 0.00 0.93 0.86 M4.93 2.75
SU2C SC_9080 9.5 NA Lymph_Node 8.Other 0.77 0.72 0.00 0.92 M2.48 M2.13 1.46
SU2C SC_9081 9.8 NA Lymph_Node 8.Other 0.86 0.48 0.00 0.92 M0.86 M3.37 2.44
SU2C SC_9083 9 NA Bone 8.Other 0.62 0.63 0.01 0.89 M3.1 M3.49 2.8
SU2C 1115202 NA NA Soft_Tissue 8.Other 0.44 0.22 0.00 0.84 5.55 M5.1 3.59
SU2C 6115123 NA NA Soft_Tissue 8.Other 0.67 1.68 0.01 0.84 M5.46 M3.65 2.73
SU2C 6115227 NA NA Soft_Tissue 8.Other 0.87 0.39 0.01 0.83 M1.33 M6.75 4.51
SU2C 6115233 NA NA Lymph_Node 8.Other 0.84 0.41 0.01 0.84 M0.9 M6.03 1.94
SU2C 6115242 NA NA Soft_Tissue 8.Other 0.49 0.89 0.01 0.79 M2.9 M4.65 4.35
SU2C 6115250.2 NA NA Lymph_Node 8.Other 0.95 0.62 0.01 0.84 2.93 M9.32 5.03
SU2C 6115251 NA NA Lymph_Node 8.Other 0.73 0.46 0.01 0.83 M0.22 M3.58 3.03
SU2C TP_2010 7.6 NA Lymph_Node 8.Other 0.73 0.66 0.01 0.89 M4.13 M7.38 1.71
SU2C TP_2032 9.4 NA Lymph_Node 8.Other 0.57 1.08 0.00 0.84 M3.54 M2.39 3.24
SU2C TP_2061 4.9 NA Soft_Tissue 8.Other 0.67 0.67 0.01 0.92 M6.08 0.05 M0.49
















































































C7orf76 C7orf76 unused, overlaps SHFM1
KIAA0408 KIAA0408 unused, overlaps SOGA3
Chromogranin A CHGA ENSG00000100604.12

























we added these, previously 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































3' Bias Comparison for TCGA Tumor Samples
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density.default(x = inv.norm.ar[, 1])





























































































































































































































































































































































































































































































































































































































density.default(x = pc.score.ar[, 1])






























density.default(x = inv.norm.ne[, 1])






























































































































































































































































































































































































































































































































































































density.default(x = pc.score.ne[, 1])

























TCGA calls, Stromal Score r^2











TCGA Calls, PrEC VFs
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